TsuyukiRTDaviesNM. Self-denigration in pharmacy: words that should be banished from the pharmacy lexicon. Can Pharm J (Ott)2014;147(4): 197-9.
2.
Al HamarnehYNCharroisTLewanczukRTsuyukiRT. Pharmacist intervention for glycaemic control in the community (the RxING study). BMJ Open2013;3:e003154.
3.
TsuyukiRTAl HamarnehYNJonesCAHemmelgarnBR. The effectiveness of pharmacist interventions on cardiovascular risk: the multicenter randomized controlled RxEACH Trial. J Am Coll Cardiol2016;67(24):2846-54.
4.
TsuyukiRTHouleSKDCharroisTLet al. Randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: the Alberta Clinical Trial in Optimizing Hypertension (RxACTION). Circulation2015;132(2):93-100.
5.
TsuyukiRTRosenthalMPearsonGJ. A randomized trial of a community-based approach to dyslipidemia management: pharmacist prescribing to achieve cholesterol targets (RxACT study). Can Pharm J (Ott)2016;149:283-92.
6.
Al HamarnehYNHemmelgarnBCurtisCet al. Community pharmacist–targeted screening for chronic kidney disease. Can Pharm J (Ott)2016;149(1):13-7.
7.
HouleSKDBascomCSRosenthalMM. Clinical outcomes and satisfaction with a pharmacist-managed travel clinic in Alberta, Canada. Trav Med Infect Dis2018;23:21-6.
8.
Al HamarnehYNLambSDonaldMet al. Pharmacist prescribing and care improves cardiovascular risk, but what do patients think? A sub-study of the RxEACH study. Can Pharm J (Ott)2018;151(4):223-7.
